Page 30 - Sofinnova Partners News Today

(1) CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). The company presented the first ever study demonstrating sensorless synchronization of a pericardial pump with the native heart for over 30 days. This breakthrough is an important step towards the finalization of the developmen...

Mission Therapeutics to Participate in Upcoming SVB Leerink Biopharma Private Company Connect Event Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event. The event, which will take place virtually on 6-7 May 2021, is intended to bring together private companies with instituti...

(0) SANTIAGO, CHILE and PARIS, FRANCE / ACCESSWIRE / April 6, 2021 / Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced today it has appointed Novozymes senior executive Thomas Videbaek as Chair of the Board of Directors and non-executive board member. Dr. Videbaek has spent the last 13 years on the executive team at Novozymes, the world leader in industrial enzymes. After three decades at the firm, which i...

April 1, 2021 By Bio-IT World Staff April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.   $969M Investment Fund for Early to Late-Stage Companies Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversu...

A sceneuron SA, an emerging leader in the development of treatments for neurodegenerative diseases, announced today the receipt of a USD 2.2 million award from the Alzheimers Drug Discovery Foundation (ADDF) for a first in human Phase I study of the Companys next generation O-GlcNAcase inhibitor, ASN51. The trial is due to recruit healthy volunteers and Alzheimers disease patients at sites in Europe and Australia, to start in Q2 2021, with first interim data due in Q3 2021. The award will su...

(Pixabay) Sofinnova Partners has pulled in a healthy €445 million ($540 million) in its latest capital raise as the European venture capital firm seeks out late-stage plays in biotech and medtech. The fund was “oversubscribed and significantly exceeded its target,” the Paris-based firm said, and with this latest cash boost its set to continue its focus on European clinical-stage companies “needing scale-up capital” while also supporting “best-in-class companies” in the U....

News | February 11, 2021 EnginZyme Extends Series A to €11M To Advance Cell-Free Chemical Production Platform In Funding Round Led by Swedens Industrifonden STOCKHOLM--(BUSINESS WIRE)-- EnginZyme, a company developing a technology platform for sustainable production of chemicals, today announced it has closed an extension to its Series A financing round, bringing the total raised to €11 million. The extension round was led by Industrifonden, Sweden’s largest de...

Posted on 7598 EnginZyme, a company developing a technology platform for sustainable production of chemicals, today announced it has closed an extension to its Series A financing round, bringing the total raised to €11 million. The extension round was led by Industrifonden, Sweden’s largest deep tech venture capital firm, followed by SEB Greentech VC and existing shareholders. “Current bio-manufacturing processes are too expens...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation. Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer February 4, 2021 GMT Catamaran CEO Alvin Shih (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 4, 2021-- Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need, today announced the appointment of Alvin Shih, M...